It has been a busy few months for healthcare investment group PureTech (PRTC). Several of its portfolio companies have reported significant developments including two drugs filings, clinical readouts, major financing rounds, a Nasdaq IPO and a collaboration with Swiss pharma group Roche. Thus, group net assets leapt over 200 per cent to £217m at the half-year point.
IC TIP:
Buy
at
156p
Meanwhile, with $197m (£151m) of cash yet to be deployed, PureTech has significant firepower for further investment, which should pave the way for more positive updates from both its portfolio companies and internal research and development. Indeed, 13 further clinical announcements are expected within the next 12 months.